News | May 31, 2021
Sun Pharmaceutical’s internals remain strong: ICICI Securities
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
The centralized marketing authorization granted by the EC is valid in all EU Member
Subscribe To Our Newsletter & Stay Updated
